Welcome to MarylandLifeScience.com
MarylandLifeScience.com is part of a specialized network of state based biotechnology, medical device,
and life science sites that includes more than 3,500 biotechnology, medical device, pharmaceutical companies,
non-profit research institutions, universities and supporting service sector companies across the U.S.
This network addresses the growing informational and service needs of companies, patients, educators and others in
their respective states while providing clients the opportunity to cost effectively
advertise their job openings, events, facility availability and other services at the state level,
regionally or nationwide. We welcome your comments, suggestions and requests for informational content and supporting
services.
More...
|
|
Learn About Maryland's BioHistory
Why is there a biotechnology industry in Maryland? Will the industry continue
to grow in Maryland? What do other states have? Each state has a unique story
that explains why a given industry has developed in a specific region and not in others.
Through Maryland BioHistory, you can learn about the scientists,
institutions, political leaders, and significant events that have shaped and are still shaping
the biotechnology, medical device and life science industries in the state of Maryland.
More MD BioHistory...
|
Local News...
Free News Release Posting & Archiving Service
- Osiris Therapeutics reports first quarter 2008 financial results Osiris Therapeutics announced its results for the first quarter of 2008. For the first quarter of 2008, Osteocel sales were $7.5 million, compared to $2.0 million for the same period of the prior year.
Osiris Therapeutics, Inc. May 09, 2008
- Redpoint Bio reports first quarter 2008 results Redpoint Bio announced financial and operational results for the first quarter ended March 31, 2008. For the quarter ended March 31, 2008, Redpoint recorded revenue of $0.9 million, which includes the Company's research and development collaboration with Givaudan.
Redpoint Bio Corporation May 09, 2008
- Bayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye Bayer HealthCare and development partner Regeneron Pharmaceuticals announced that the first patient has been dosed in the new VIEW 2 trial, a second Phase 3 clinical study in a development program evaluating VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration.
Bayer May 08, 2008
- Osiris receives approval for use of Prochymal under FDA expanded access treatment program Osiris Therapeutics announced it has been given clearance by the U.S. Food and Drug Administration to initiate an expanded access treatment program for Prochymal, making the investigational stem cell product available to children with life-threatening Graft vs. Host Disease.
Osiris Therapeutics, Inc. May 08, 2008
- AstraZeneca submits sNDA for Seroquel XR for the treatment of generalised anxiety disorder AstraZeneca announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration for SEROQUEL XR(TM) Extended-Release Tablets to seek approval for the treatment of generalised anxiety disorder, including maintenance of antianxiety effect.
AstraZeneca May 08, 2008
More... | Submit News Release | National News
|